Abstract:
The invention provides compounds of formula (I) in salt or zwitterionic form or a pharmaceutically acceptable salt thereof, wherein R 1-6, a-e and Q are as defined in the specification,. These compounds are muscarinic receptor antagonists. The invention also provides pharmaceutical compositions containing such compounds, processes for preparing such compounds and methods of using such compounds to, for example, treat pulmonary disorders such as chronic obstructive pulmonary disease and asthma.
Abstract:
Compounds of a certain formula (I), in which R1, R2, R3, R4, R5, R6 and R7 have the meanings indicated in the description, as well as salts thereof are novel effective HDAC inhibitors.
Abstract:
The invention relates to pyrrolopyridine derivative compounds having general formula (I) as defined in the claims and to the pharmaceutically-acceptable addition salts thereof. The invention also relates to the method of preparing the aforementioned compounds, to pharmaceutical compositions containing same and to the use thereof as a pharmacologically-active substance, for example in the treatment of hypertriglyceridaemias, hyperlipidemias, hypercholesterolemias, diabetes, endothelial dysfunction, cardiovascular and inflammatory diseases and neurodegeneration.
Abstract:
A sulfonate salt and a derivative thereof are provided to be effectively used as a raw material of a photoacid generator of a resist material or a photoacid generator by inhibiting the dissolution in water and controlling the formation of foreign matter inherent to the ArF immersion lithography. A sulfonate salt is represented by the formula(1) of R^1COOCH2CH2CF2CF2SO3^-M^+(R^1 is a substituted or unsubstituted C1-20 linear, branched or cyclic alkyl, a substituted or unsubstituted C6-15 aryl, or a C4-15 heteroaryl, and M^+ is a lithium, sodium, potassium, ammonium, or tetramethylammonium ion). A photoacid generator for a chemically amplified resist composition generates a sulfonic acid represented by the formula(1a) of R^1COOCH2CH2CF2CF2SO3^-H^+ upon exposure to high-energy radiation selected from UV, deep-UV, electron beam, x-ray, excimer laser, gamma-ray and synchrotron radiation. A resist composition comprises a base resin, an acid generator, and an organic solvent, wherein the acid generator comprises a photoacid generator which generates the sulfonic acid of the formula(1a). A chemically amplified positive resist composition comprises a base resin, a photoacid generator which generates a sulfonic acid of the formula(1a), and a solvent, wherein the base resin is insoluble or substantially insoluble in a liquid developer, and becomes soluble under the action of the acid. A method for forming a pattern comprises the steps of: (a) applying the resist composition onto a substrate to form a coating; (b) heat-treating the coating and exposing it to high-energy radiation having a wavelength of up to 300 nm through a photomask; and (c) optionally heat-treating and developing the exposed coating with a developer.
Abstract:
The present invention relates to pyrrolidine derivatives and dimeric forms and/or pharmaceutically acceptable esters, and/or salts thereof. The compounds are useful as inhibitors of metalloproteases, e.g. zinc proteases, particularly zinc hydrolases, and which are effective in treating disease states are associated with vasoconstriction of increasing occurrences.
Abstract:
Compounds of the formula:wherein R1 to R7 and Y are as defined in the specification, and pharmaceutically acceptable salts and/or pharmaceutically acceptable esters thereof, are useful for treating diseases associated with cystein proteases, such as osteoporosis, osteoarthritis, rheumatoid arthritis, tumor metastasis, glomerulonephritis, atherosclerosis, myocardial infarction, angina pectoris, instable angina pectoris, stroke, plaque rupture, transient ischemic attacks, amaurosis fugax, peripheral arterial occlusive disease, restenosis after angioplasty and stent placement, abdominal aortic aneurysm formation, inflammation, autoimmune disease, malaria, ocular fundus tissue cytopathy and respiratory disease.
Abstract:
1-Arenesulfonyl-2-Aryl-pyrrolidine and pyridine derivatives having activity as ligands of metabotropic glutamate receptors of the formulaare disclosed.
[식 중, R 1 은 수소 원자, 할로겐 원자, 알킬기 또는 수산기를 나타내고, R 2 는 수소 원자 또는 할로겐 원자를 나타내고, R 3 은 수소 원자, 치환될 수 있는 알킬기, 아랄킬기, 치환될 수 있는 알킬카르보닐기, 치환될 수 있는 알킬술포닐기 등을 나타내고, R 4 및 R 5 는 각각 수소 원자, 할로겐 원자, 치환될 수 있는 알킬기, 카르바모일기 등을 나타내고, R 6 은 헤테로환 등을 나타내고, R 7 및 R 8 은 각각 수소 원자, 알킬기 등을 나타내고, n 은 0, 1 또는 2 를 나타냄] 으로 표시되는 화합물 및 그 약리상 허용될 수 있는 염은 우수한 활성화 혈액 응고 제 X 인자 저해 활성을 나타내며, 혈액 응고관련 질환의 예방 또는 치료를 위해 유용하다.